Results 141 to 150 of about 82,921 (179)
Some of the next articles are maybe not open access.
Pharmacotherapy, 2014
l‐asparaginase is an aminohydrolase that deprives leukemia cells of l‐asparagine required for protein synthesis. Although studies in patients with acute lymphoblastic leukemia have shown that the addition of l‐asparaginase improved the overall remission rate, life‐threatening acute pancreatitis has occurred in 0.5–4% of patients.
Larry W, Buie +2 more
exaly +3 more sources
l‐asparaginase is an aminohydrolase that deprives leukemia cells of l‐asparagine required for protein synthesis. Although studies in patients with acute lymphoblastic leukemia have shown that the addition of l‐asparaginase improved the overall remission rate, life‐threatening acute pancreatitis has occurred in 0.5–4% of patients.
Larry W, Buie +2 more
exaly +3 more sources
Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice [PDF]
European Journal of Pharmaceutical Sciences, 2016 The potential impact of pre-existing anti-PEG antibodies on the asparaginase activity kinetics of two pegylated L-Asparaginase preparations -pegylated recombinant L-Asparaginase (PEG-rASNase MC0609) and pegaspargase (pegylated E.
Ralf Kraehmer +2 more
exaly +2 more sources
Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study [PDF]
Veterinary Journal, 2022 L-asparaginase is a frequently used drug in the treatment of canine malignant lymphoma. Since production and availability of native E. coli-derived L-asparaginase are limited, PEG-L-asparaginase (PEG-ASP) is an alternative. However, recommended doses and
Ronette Gehring, , K Vandemeulebroecke
exaly +6 more sources
PEG-Adenosine Deaminase and PEG-Asparaginase
Talanta, 2005Because of its extended blood circulating life, fewer injections of smaller amounts of Oncaspar than unmodified asparaginases are required to maintain blood asparagine levels at low, therapeutically effective levels. While immune responses do occur with Oncaspar they are fewer than with unmodified asparaginases. Oncaspar might be even more effective if
C, John +4 more
openaire +4 more sources
Expert Opinion on Pharmacotherapy, 2007
L-asparaginases have been established components in the treatment of acute leukemias for nearly 40 years. Their antitumor effect results from the depletion of asparagine, an amino acid essential to leukemic cells, and subsequent inhibition of protein synthesis leading to considerable cytotoxicity.
Cecilia H, Fu, Kathleen M, Sakamoto
openaire +2 more sources
L-asparaginases have been established components in the treatment of acute leukemias for nearly 40 years. Their antitumor effect results from the depletion of asparagine, an amino acid essential to leukemic cells, and subsequent inhibition of protein synthesis leading to considerable cytotoxicity.
Cecilia H, Fu, Kathleen M, Sakamoto
openaire +2 more sources
HLA-DRB1 *16:02 is Associated with PEG-Asparaginase Hypersensitivity
Pharmacogenomics, 2021Aim: To evaluate the associations between human leukocyte antigen (HLA)-DRB1 variants and the rs6021191 variant in nuclear factor of activated T cells 2 (NFATC2) with PEG-asparaginase hypersensitivity in children with acute lymphoblastic leukemia (ALL) treated according to the Chinese Children Leukemia Group (CCLG) ALL 2018 protocol.
Shuguang, Liu +8 more
openaire +2 more sources
Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials
Journal of Oncology Pharmacy Practice, 2020Asparaginase (ASNase) use as a tumour-inhibitor drug has changed completely the natural course of paediatric acute lymphoblastic leukaemia (ALL) in such a way that it represents a paradigm shift in ALL management. ASNase treatment emergence has significantly improved pathologic responses and increased survival rates of ALL patients.
María M Viña-Romero +5 more
openaire +2 more sources
Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase
Journal of Pediatric Hematology/Oncology, 2020Polyethylene glycosylated (PEG)-asparaginase is a cornerstone of treatment for acute lymphoblastic leukemia (ALL), and effective administration is associated with better outcomes. PEG-asparaginase is associated with a uniphasic hypersensitivity reaction in ∼10% to 20% of patients.
Shelby A, Fertal +3 more
openaire +2 more sources
Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL)
Blood, 2002Asparaginase (ASNase) has long been considered to be an important element in the management of childhood ALL. Its antileukemic effect is thought to be related to a metabolic deficiency reflected by the blasts' incapability to synthesize asparagine (ASN) from aspartic acid.
Joao Paulo Vieira, Pinheiro +3 more
openaire +2 more sources
Peg-asparaginase for acute lymphoblastic leukemia
Expert Opinion on Biological Therapy, 2010Asparaginase is a prominent component of pediatric and adolescent treatment for acute lymphoblastic leukemia. These treatment regimens are now being employed in adults. Knowledge of the efficacy and toxicity of asparaginase preparations is essential when using these treatments.
openaire +2 more sources